France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer’s Disease

Manuscript Number: 

18-0843

Author(s): 
Hélène Amiéva, Sandrine Andrieu, Jean-Philippe Delabrousse-Mayoux, Bruno Dubois, Claude Jeandel, Pierre Krolak-Salmon, Armand Perret-Liaudet, François Sellal, Pierre Vandel

Disclosures

Hélène Amiéva

  • Nothing to Disclose

Sandrine Andrieu

  • Consulting Fees:
    Nestlé, Lilly

Jean-Philippe Delabrousse-Mayoux

  • Consulting Fees:
    Novartis. Gilenya Board

Bruno Dubois

  • Consulting Fees:
    Bruno DUBOIS has received consultant fees from Biogen and Boehringer Ingelheim.
    Grants
    • Agency: 
      Roche
      Dates: 
      2012
    • Agency: 
      Merck
      Dates: 
      2016

Claude Jeandel

  • Nothing to Disclose

Pierre Krolak-Salmon

  • Consulting Fees:
    Consulting fees and participation to advisory boards, but none regarding the drugs mentioned in the article
    Lecture Fees:
    Lecture fees, but none regarding the drugs mentioned in the article
    Grants
    • Agency: 
      MSD Avenir
      Dates: 
      2017

Armand Perret-Liaudet

  • Consulting Fees:
    Consulting fee by Fujirebio Europe company, March 2018 in the field of AD CSF biomarkers (1000 euros).

François Sellal

  • Lecture Fees:
    Lecture fees from SANOFI, Biogen, Novartis-Pharma.

Pierre Vandel

  • Lecture Fees:
    Symposium "Repenser la dépression". Fees as a speaker on January and february 2017. Lundbeck.